Health
Almirall Announces "LumiNE", a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
BARCELONA, Spain, January 15, 2026--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, announces the planned start of a phase III study assessing the efficacy and safety of Lebrikizumab (Ebglyss®, currently approved for the treatment of moderate-to-severe atopic dermatitis) in patients with nummular eczema. This study will be initiated in the first half of 2026 and is aligned with Almirall’s ambition of leadership in medical dermatology and is part of the ong
About this update from Almirall Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":210,"url":"https://media.zenfs.com/en/business-wire.com/f145c600407bbdf540511d499946a5c6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5JRA9MfMiqs_HHi.Q7ekUw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f145c600407bbdf540511d499946a5c6","width":480,"height":210}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease mechanisms including IL-13 and therefore makes targeting IL-13 with lebrikizumab a potentially promising therapeutic option.","length":242,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"LumiNE is part of Almirall’s ongoing lifecycle management activities to enable more patients to benefit from advanced treatments - such as Lebrikizumab - targeting patients with dermatological conditions and high unmet medical needs.","length":233,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The phase III study will be initiated within the first half of 2026 and will evaluate the efficacy, safety, and tolerability of lebrikizumab in at least 270 patients with nummular eczema in Europe for up to 48 weeks of treatment.","length":229,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":704,"olType":false},{"type":"text","content":"BARCELONA, Spain, January 15, 2026--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, announces the planned start of a phase III study assessing the efficacy and safety of Lebrikizumab (Ebglyss®, currently approved for the treatment of moderate-to-severe atopic dermatitis) in patients with nummular eczema. This study will be initiated in the first half of 2026 and is aligned with Almirall’s ambition of leadership in medical dermatology and is part of the ongoing lifecycle management activities Almirall is conducting for its products to enable more patients to benefit from advanced treatments targeting dermatological conditions with high unmet medical need.","length":719,"tagName":"p"},{"type":"text","content":"Nummular eczema is distinct condition from atopic dermatiti...